1 in 7 Americans suffer from Asthma or COPD.
Many more people may have COPD but remain undiagnosed.
Respiratory conditions are complex to treat because of intertwined psychosocial and environmental issues. Outcomes depend on more than pharmacological treatments.
Nightingale addresses all of these issues on a scalable virtal care platform proven to improve outcomes and reduce costs.
AI-driven lung-sound monitoring device, ADAMM, provides personal monitoring and feedback. ADAMM is to Asthma and COPD what the CGM is to Diabetes.ADAMM delivers insights that are proven to generate significant improvements in quality of life, symptom reduction and sleep quality.Ease of use, immediate results, and personalized feedback from device drive engagement.
Coordinated care includes Respiratory Therapists and Asthma Educators Sub-clinical resources proven to reduce costs associated with uncontrolled asthma and COPD Built-in accommodations for Social Determinants of Health
Nightingale combines virtual home-based asthma and COPD interventions with cutting- edge respiratory monitoring and self-management education. Program based on the same interventions but with no technology have consistently shown positive ROIs ranging from $1.90 per $1 invested to $20 per $1 invested1. Time to realization ranged from 1-4 years. Nightingale demonstrates clinically efficacious improvement in symptoms and quality of life within 6 months. Increased ROI due to decreased upfront and operational costs and a more scalable long-term engagement approach versus traditional approaches are likely to drive even greater savings for you and your members.
Hsu J,Wilhelm N, Lewis L, Herman E,Economic Evidence for US Asthma Self-Management Education and Home-Based Interventions. J AllergyClinlmmunol Pract.2016;4(6):1123-1134.e27. doi:10.1016/j.jaip.2016.05.012